Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.89 |
| ▸ | NSD2 | O96028 | 1/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
| ▸ | BID | P55957 | 1/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.89 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.89 |
| ▸ | ASPH | Q12797 | 1/20 | 0.89 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.89 |
| ▸ | BAD | Q92934 | 1/20 | 0.89 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.89 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373366 | 1.00 | BCL2 (1.00) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL1701672 | 0.98 | BCL2 (0.96) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL30313746 | 0.98 | BCL2 (0.96) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL29376500 | 0.97 | BCL2 (0.94) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL20580433 | 0.97 | BCL2 (0.94) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL19839513 | 0.97 | BCL2 (1.00) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL29376560 | 0.97 | BCL2 (1.00) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL20580416 | 0.96 | BCL2 (0.92) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL29376533 | 0.96 | BCL2 (0.92) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL1701418 | 0.95 | BCL2 (0.91) | BCL2BCL2L1NSD2ADORA3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053815-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-3843751-B1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2024-03-27 | — | — | EP | disclosed |
| EP-3672591-B1 | SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-10829488-B2 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3494115-B1 | N-(PHENYLSULFONYL)BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200222393-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR OR BCL-2/BCL-XL DUAL INHIBITOR AND BTK INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-16 | — | — | US | disclosed |
| US-20200222393-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR OR BCL-2/BCL-XL DUAL INHIBITOR AND BTK INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-16 | — | — | US | disclosed |
| EP-3569601-A2 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents of The University of Michigan (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-17 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL3, BCL6 | BCL2 8/4885BCL2L1 7/4885NSD2 2490/4885 |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, PNLIP | BCL2 43/4885BCL2L1 39/4885NSD2 3464/4885 |
| US-10221174-B2 | N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885BCL2L1 6/4885NSD2 214/4885 |
| US-20180354950-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | BCL2 3/4885BCL2L1 6/4885NSD2 214/4885 |
| US-10829488-B2 | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885BCL2L1 6/4885NSD2 202/4885 |
| US-20200222393-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR OR BCL-2/BCL-XL DUAL INHIBITOR AND BTK INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL2, BCL2L2, BCL2L1 | BCL2 1/4885BCL2L1 3/4885NSD2 1292/4885 |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | BCL2, BCL3, BCL2L13 | BCL2 1/4885BCL2L1 6/4885NSD2 1605/4885 |
| US-20260053815-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL3, BCL2, BCL2L1 | BCL2 2/4885BCL2L1 3/4885NSD2 988/4885 |
| US-20190315739-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | BCL2A1, BCL3, BCL2 | BCL2 3/4885BCL2L1 6/4885NSD2 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.